(LAB) Standard Biotools - Overview
Stock: Instruments, Consumables, Software, Services, Platforms
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 73.3% |
| Relative Tail Risk | -7.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -37.64 |
| Character TTM | |
|---|---|
| Beta | 1.472 |
| Beta Downside | 1.269 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.78% |
| CAGR/Max DD | -0.22 |
Description: LAB Standard Biotools December 28, 2025
Standard BioTools Inc. (NASDAQ: LAB) develops, manufactures, and sells instrumentation, consumables, software, and services for proteomics and genomics research across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The company’s two operating segments-Proteomics and Genomics-serve academic institutions, translational research centers, cancer and clinical labs, as well as biopharma, biotech, and agricultural research firms.
Key platforms include the SomaScan® proteomics assay (high-throughput protein quantification), CyTOF™ mass-cytometry (metal-tagged antibody detection), the Hyperion™ spatial biology system (high-dimensional tissue mapping), and the Biomark X9 qPCR platform (large-scale genomics). Licensing partnerships with Caltech, Harvard, and Caliper Life Sciences bolster its technology pipeline and expand market reach.
In FY 2023 the company reported revenue of roughly $272 million, a 9 % YoY increase driven primarily by growth in its spatial-omics and high-throughput proteomics lines; gross margin held near 68 %, and cash and short-term investments topped $150 million, providing runway for R&D and potential acquisitions. The broader life-sciences tools market is expanding at an estimated 8-9 % CAGR, fueled by rising biotech R&D spend and the increasing adoption of multiplexed, high-content assays-trends that directly benefit Standard BioTools’ addressable opportunity set. For a deeper dive into the company’s valuation dynamics, a quick look at ValueRay’s analyst notes may prove useful.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -128.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 3.55 > 1.0 |
| NWC/Revenue: 282.9% < 20% (prev 235.8%; Δ 47.07% < -1%) |
| CFO/TA -0.16 > 3% & CFO -87.2m > Net Income -128.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (382.6m) vs 12m ago 2.99% < -2% |
| Gross Margin: 47.94% > 18% (prev 0.50%; Δ 4743 % > 0.5%) |
| Asset Turnover: 21.10% > 50% (prev 20.72%; Δ 0.38% > 0%) |
| Interest Coverage Ratio: -32.16 > 6 (EBITDA TTM -93.6m / Interest Expense TTM 3.34m) |
Altman Z'' -14.08
| A: 0.68 (Total Current Assets 472.4m - Total Current Liabilities 108.0m) / Total Assets 539.6m |
| B: -2.37 (Retained Earnings -1.28b / Total Assets 539.6m) |
| C: -0.18 (EBIT TTM -107.3m / Avg Total Assets 610.6m) |
| D: -9.14 (Book Value of Equity -1.28b / Total Liabilities 140.0m) |
| Altman-Z'' Score: -14.08 = D |
Beneish M -4.00
| DSRI: 0.42 (Receivables 13.5m/35.3m, Revenue 128.8m/141.2m) |
| GMI: 1.05 (GM 47.94% / 50.41%) |
| AQI: 0.19 (AQ_t 0.04 / AQ_t-1 0.23) |
| SGI: 0.91 (Revenue 128.8m / 141.2m) |
| TATA: -0.08 (NI -128.3m - CFO -87.2m) / TA 539.6m) |
| Beneish M-Score: -4.08 (Cap -4..+1) = AAA |
What is the price of LAB shares?
Over the past week, the price has changed by -10.00%, over one month by -0.79%, over three months by +12.50% and over the past year by -11.27%.
Is LAB a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.6 | 23% |
| Analysts Target Price | 1.6 | 23% |
| ValueRay Target Price | 1.1 | -9.5% |
LAB Fundamental Data Overview February 02, 2026
P/B = 1.3568
Revenue TTM = 128.8m USD
EBIT TTM = -107.3m USD
EBITDA TTM = -93.6m USD
Long Term Debt = 299.0k USD (from longTermDebt, last quarter)
Short Term Debt = 5.11m USD (from shortTermDebt, last quarter)
Debt = 27.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.0m USD (from netDebt column, last quarter)
Enterprise Value = 436.4m USD (538.4m + Debt 27.4m - CCE 129.4m)
Interest Coverage Ratio = -32.16 (Ebit TTM -107.3m / Interest Expense TTM 3.34m)
EV/FCF = -4.43x (Enterprise Value 436.4m / FCF TTM -98.4m)
FCF Yield = -22.55% (FCF TTM -98.4m / Enterprise Value 436.4m)
FCF Margin = -76.40% (FCF TTM -98.4m / Revenue TTM 128.8m)
Net Margin = -99.55% (Net Income TTM -128.3m / Revenue TTM 128.8m)
Gross Margin = 47.94% ((Revenue TTM 128.8m - Cost of Revenue TTM 67.1m) / Revenue TTM)
Gross Margin QoQ = 48.51% (prev 48.84%)
Tobins Q-Ratio = 0.81 (Enterprise Value 436.4m / Total Assets 539.6m)
Interest Expense / Debt = 0.04% (Interest Expense 10.0k / Debt 27.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.8m (EBIT -107.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.38 (Total Current Assets 472.4m / Total Current Liabilities 108.0m)
Debt / Equity = 0.07 (Debt 27.4m / totalStockholderEquity, last quarter 399.7m)
Debt / EBITDA = 1.09 (negative EBITDA) (Net Debt -102.0m / EBITDA -93.6m)
Debt / FCF = 1.04 (negative FCF - burning cash) (Net Debt -102.0m / FCF TTM -98.4m)
Total Stockholder Equity = 437.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.00% (Net Income -128.3m / Total Assets 539.6m)
RoE = -29.31% (Net Income TTM -128.3m / Total Stockholder Equity 437.6m)
RoCE = -24.51% (EBIT -107.3m / Capital Employed (Equity 437.6m + L.T.Debt 299.0k))
RoIC = -19.36% (negative operating profit) (NOPAT -84.8m / Invested Capital 437.9m)
WACC = 10.79% (E(538.4m)/V(565.8m) * Re(11.34%) + D(27.4m)/V(565.8m) * Rd(0.04%) * (1-Tc(0.21)))
Discount Rate = 11.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 119.1%
Fair Price DCF = unknown (Cash Flow -98.4m)
EPS Correlation: 80.79 | EPS CAGR: 197.0% | SUE: 0.81 | # QB: 0
Revenue Correlation: 12.05 | Revenue CAGR: -16.39% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.04 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+63.6% | Growth Revenue=-0.7%